TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28145919
Drug: 3-minute rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-minute rest interval (G-3 min)
Study: 25887099
Drug: Selumetinib 75mg
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75mg PO BID administered daily until progression or intolerance, one cycle was 28 days.
Study: 22926324
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mL/kg)
Study: 21487148
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d of L-leucine
Study: 19653973
Drug: Novo-venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novo-venlafaxine XR 75 mg
Study: 19653973
Drug: Effexor XR
Normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effexor XR 75 mg
Study: 19653973
Drug: Gen-citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gen-citalopram 40 mg
Study: 19653973
Drug: Celexa 40
Normalized name: Celexa 40mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celexa 40 mg
Study: 15302319
Drug: Ibuprofen (antiprostaglandin)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (antiprostaglandin)
Study: 9486567
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (two cycles of cisplatin, vincristine, peplomycin, with or without mitomycin C)
Study: 9486567
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with or without peplomycin chemotherapy (Group A)
Study: 9486567
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy with or without concomitant peplomycin chemotherapy followed by surgery (Group B)
Study: 8018525
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (subcutaneous reservoir of rIFN-gamma injections)
Study: 2555713
Drug: 3,4-Diaminopyridine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-Diaminopyridine (up to 100 mg per day)
Study: 28482639
Drug: Control (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tablet computer training) (n = 51)
Study: 24012146
Drug: Selenium-silymarin mix
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-silymarin mix (240μg selenium plus 570mg silymarin daily for 6 months)
Study: 20888671
Drug: Preservative-free propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free propofol infusion
Study: 16525231
Drug: Tetavax (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetavax (licensed monovalent tetanus‐toxoid vaccine)
Study: 10634404
Drug: GAD65-CAb in
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD65-CAb in insulin-treated subjects
Study: 10634404
Drug: GAD65-CAb in
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD65-CAb in subjects treated with hypoglycemic agents and/or diet
Study: 10634404
Drug: GAD65-MAb in
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD65-MAb in subjects treated with hypoglycemic agents and/or diet
Study: 29503112
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of MenACWY-TT at month 0 (ACWY_1)
Study: 29503112
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MenACWY-TT at month 0 and month 2 (ACWY_2)
Study: 29503112
Drug: MenACWY-TT and
Normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT and PCV13 co-administered at month 0 (Co-ad)
Study: 12218423
Drug: Risperidone (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.02 to 0.06 mg/kg per day)
Study: 9832297
Drug: Dipyrone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (two 0.5-g tablets)
Study: 8076441
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% sodium fusidate ointment applied in the anterior nares and in the pericatheter skin twice daily for 5 days
Study: 8076441
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 200 mg taken every 48 hours for 5 days
Study: 1195474
Drug: Sulfacytine 1
Normalized name: SULFACYTINE
DrugBank: Sulfacytine (DB01298)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfacytine 1 gm daily for 10 days
Study: 1195474
Drug: Sulfisoxazole 4
Normalized name: sulfisoxazole 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole 4 gm daily for 10 days
Study: 27149410
Drug: Appetite-focused cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appetite-focused cognitive-behavioural therapy
Study: 22539562
Drug: TEC (paclitaxel/carboplatin/epirubicin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (paclitaxel/carboplatin/epirubicin; 75 mg/m2 i.v.)
Study: 22539562
Drug: TC (paclitaxel/carboplatin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (paclitaxel/carboplatin; AUC 5 and 175 mg/m2)
Study: 15616084
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of morphine
Study: 15616084
Drug: 0.05 mL
Normalized name: xenon 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mL of saline (control group)
Study: 10360204
Drug: Hydroxyzine (HYZ)
Normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine (HYZ) 3.7 mg/kg
Study: 10360204
Drug: Hydroxyzine (HYZ)
Normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine (HYZ) 3.7 mg/kg + Metoclopramide (MTP) 5 mg
Study: 7865500
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with the anticholinergic biperiden
Study: 1827005
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg or 2.5 mg twice daily orally for one year
Study: 1827005
Drug: Isradipine with
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine with beta-blocker bopindolol
Study: 6808225
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (neomycin, colistin, and nystatin) in conventional ward isolation
Study: 6808225
Drug: Strict isolation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict isolation, filtered air, sterilized food and oral antibiotics
Study: 6808225
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for gut flora suppression in conventional ward isolation
Study: 31090746
Drug: Trans-sinus implants
Normalized name: sinusitisinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-sinus implants without simultaneous bone grafting (group 1, n = 16)
Study: 31090746
Drug: Trans-sinus implants
Normalized name: sinusitisinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2, n = 16)
Study: 31090746
Drug: Trans-sinus implants
Normalized name: sinusitisinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-sinus implants without simultaneous bone grafting (group 1)
Study: 31090746
Drug: Trans-sinus implants
Normalized name: sinusitisinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2)
Study: 18437797
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants
Study: 26669545
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants
Study: 28294200
Drug: Maxilla implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxilla implants
Study: 28294200
Drug: Mandible implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandible implants
Study: 28294200
Drug: Immediate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate and delayed implants
Study: 15886837
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and teeth brushing with YAHAO toothpaste (eugenol and borax cream)
Study: 11964594
Drug: Breathing room
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing room air at hemoglobin concentration of 5.7 +/- 0.3 g/dl
Study: 10213010
Drug: irinotecan (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan (350 mg/m2 every 3 weeks)
Study: 23379651
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) with metformin
Study: 23379651
Drug: rFSH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH with metformin
Study: 17933162
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg x kg(‐1) caudal morphine
Study: 17933162
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg x kg(‐1) caudal morphine
Study: 17933162
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg x kg(‐1) caudal morphine
Study: 10740331
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg piperazine oestrone sulphate + 0.7 mg norethisterone (highEP)
Study: 10740331
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg piperazine oestrone sulphate + 0.35 mg norethisterone (lowEP)
Study: 10740331
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐oestradiol continuously combined with 1 mg norethisterone acetate (E2+NETA)
Study: 10740331
Drug: All hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormone groups (highEP, lowEP, E2+NETA)
Study: 8472696
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink (5.0 ml.kg‐1 body weight of a 19.7% carbohydrate drink)
Study: 30970442
Drug: PPI plus
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI plus alginate (combination)
Study: 26377199
Drug: Iron-fortified complementary
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified complementary food (CF-FeFum) with 2 mg iron as NaFeEDTA and 3.8 mg iron as ferrous fumarate 6 days per week (n=126)
Study: 26377199
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of porridge, an iron-fortified CF with the composition currently on the Ivorian market (CF-FePP) providing 2 mg iron as NaFeEDTA and 3.8 mg iron as ferric pyrophosphate 6 days per week (n=127)
Study: 11418354
Drug: Escalating interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating interferon dose (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months; escalated to 9 MU at 6 weeks if HCV RNA detectable at 4 weeks)
Study: 11418354
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months)
Study: 9545672
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 10.0 mg/kg
Study: 9545672
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 21.4 mg/kg
Study: 9545672
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) 40.0 mg/kg
Study: 8393638
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 1 mg twice per day (n = 7)
Study: 3540504
Drug: Clonidine (CLO)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (CLO) 0.36 mg daily
Study: 3540504
Drug: Propranolol (PRO)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PRO) 160 mg daily
Study: 3540504
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 70 mg daily
Study: 26711179
Drug: High-dose ergocalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ergocalciferol (vitamin D2)
Study: 21852389
Drug: Epley maneuver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epley maneuver + 24 mg betahistine 2 times daily for 1 week
Study: 21852389
Drug: Epley maneuver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epley maneuver + placebo 2 times daily for 1 week
Study: 14551301
Drug: Intranodal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranodal (IN) administration of peptide-pulsed DC vaccines
Study: 14551301
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) administration of peptide-pulsed DC vaccines
Study: 14551301
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of peptide-pulsed DC vaccines
Study: 1813067
Drug: Cytosol protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytosol protein content (4.15 mg/ml cut-off)
Study: 6337769
Drug: Triamterene (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (200 mg)
Study: 6337769
Drug: Frusemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (80 mg daily) with indomethacin (150 mg daily)
Study: 6337769
Drug: Spironolactone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (300 mg) with indomethacin (150 mg daily)
Study: 6337769
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg) with indomethacin (150 mg daily)
Study: 6337769
Drug: Triamterene (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (200 mg) with indomethacin (150 mg daily)
Study: 31943506
Drug: 3-month fluoropyrimidine-oxaliplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Study: 31943506
Drug: 6-month fluoropyrimidine-oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Study: 14720527
Drug: Admission troponin
Normalized name: atropine sulfate Ophthalmic Solution [Ocu-tropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission troponin T (tnT) >/=0.1 microg/l (n=116)
Study: 14720527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tnT elevation and no ST-segment resolution
Study: 8295050
Drug: Morphine (MS)
Normalized name: morphine Extended Release Oral Tablet [MS Contin]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MS)
Study: 24461903
Drug: Losmapimod 15
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 15 mg
Study: 24461903
Drug: Losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 7.5 mg
Study: 24461903
Drug: Losmapimod 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 2.5 mg
Study: 26033641
Drug: Losmapimod 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 7.5 mg and 15 mg
Study: 16079172
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (etanercept 25 mg twice weekly + methotrexate up to 20 mg weekly)
Study: 16079172
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) up to 20 mg weekly
Study: 16079172
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy and etanercept
Study: 12545341
Drug: basiliximab 1
Normalized name: basiliximab 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: basiliximab 1 x 40-mg group
Study: 12545341
Drug: basiliximab 2
Normalized name: basiliximab 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: basiliximab 2 x 20-mg group
Study: 10924561
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (180 mL of iopromide containing 370 mg of iodine per milliliter)
Study: 10924561
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (180 mL of iopromide containing 300 mg of iodine per milliliter)
Study: 8831332
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 micrograms/kg bolus followed by infusion at 2 micrograms.kg-1.h-1)
Study: 8831332
Drug: Clonidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (4 micrograms/kg bolus followed by infusion at 4 micrograms.kg-1.h-1)
Study: 3973383
Drug: 6 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 micrograms HA of trivalent surface-antigen influenza virus vaccine
Study: 3678549
Drug: Tenoxicam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (oral and intradermal administration)
Study: 3678549
Drug: Tenoxicam, piroxicam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam, piroxicam, and benoxaprofen (10-40 micrograms/ml) in vitro
Study: 25813447
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg once daily) for 8 to 16 weeks
Study: 23649780
Drug: Shock absorption
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock absorption (both groups)
Study: 11025394
Drug: Phyto Hypophyson
Normalized name: phytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyto Hypophyson L
Study: 8979740
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no amiodarone therapy)
Study: 1632533
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg IV)
Study: 6152615
Drug: Common emulsion
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common emulsion antacid
Study: 30794574
Drug: Overall readability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall readability and comprehensibility of medication labels
Study: 25171074
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 2%
Study: 25171074
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 3.5%
Study: 25171074
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 5%
Study: 25171074
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 8%
Study: 25171074
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel 12%
Study: 20616293
Drug: Family medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family medicine setting (n = 116)
Study: 18199105
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg
Study: 17765245
Drug: Gliclazone 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazone 80 mg
Study: 19496272
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily, commencing at least 2 weeks before planned PICA
Study: 2668397
Drug: Thymomodulin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin (120 mg/day)
Study: 326332
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of triamcinolone
Study: 22142020
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg x kg(‐1) body mass
Study: 22142020
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg x kg(‐1) body mass
Study: 15237003
Drug: Soy phytoestrogens
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy phytoestrogens (150 mg of isoflavones per day) for 5 years
Study: 15237003
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 5 years
Study: 12564661
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care with atorvastatin 10-80 mg
Study: 12564661
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care with atorvastatin 10-20 mg
Study: 9173270
Drug: Accelerated thrombolytic
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated thrombolytic therapy with recombinant tissue plasminogen activator (t-PA)
Study: 9173270
Drug: Primary coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary coronary angioplasty with heparin